Professor Klaus Dugi

Boehringer Ingelheim announced new data analyses show positive treatment effect of Pradaxa® (dabigatran etexilate) in patients with acute deep vein thrombosis or pulmonary embolism

For media outside of the US, the UK & Canada only The efficacy and safety profile of Pradaxa® (dabigatran etexilate)…

10 years ago

950 treatment naïve genotype-1b patients enrolled for two of Boehringer Ingelheim pivotal Phase III interferon-free hepatitis C clinical trials

Over 950 patients have now been successfully enrolled in the pivotal Phase III HCVerso™1 and 2 trials The Phase III…

11 years ago

Boehringer Ingelheim to unveil new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 in Amsterdam

For media outside of the US, the UK & Canada only Ingelheim, Germany, 26-8-2013 — /EuropaWire/ — Boehringer Ingelheim today announced the…

11 years ago